Augmenix Ranked as One of America’s Fastest-Growing Private Companies for Second Year
Augmenix Maintains Spot in Top 10% of Metro-Boston Companies; Three-Year Growth over 2,000% Ranked Company Number 207 on Inc. Magazine’s Top 500
BEDFORD, Read more...
Sera Prognostics Receives Accreditation from College of American Pathologists
SALT LAKE CITY, June 29, 2017 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s healthcare company, announced today that the Accreditation Committee Read more...
Augmenix Announces First Prostate Cancer Patients Treated with SpaceOAR® Hydrogel in Israel
The Chaim Sheba Medical Center now offers the hydrogel spacer to reduce side-effects during prostate cancer radiation therapy
June 28, 2017 03:14 PM Eastern Read more...
LabCorp Exclusively Launches Sera Prognostics’ PreTRM Test to Assess for Risk of Preterm Birth
The PreTRM Test is the Only Validated Test That Provides Early and Individualized Evaluation of Preterm Birth Risk
BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp® Read more...
Sera Prognostics Appoints Nadia Altomare as Chief Commercial Officer
SALT LAKE CITY, May 17, 2017– Sera Prognostics, Inc., a women’s healthcare company, announced today that Nadia F. Altomare has joined the company as Read more...
Augmenix Announces First Prostate Cancer Patient Treated with SpaceOAR® Hydrogel in Canada
Princess Margaret Cancer Centre to initiate a 20-patient pilot study to assess hydrogel spacer to reduce rectal toxicity during prostate cancer radiation Read more...
Sera Prognostics is Named a 2017 Silver Edison Award Winner
PreTRM® Test Wins at New York Ceremony; Awards Celebrate 30 Years of Honoring Innovators and Innovation
NEW YORK, April 21, 2017 (GLOBE NEWSWIRE) -- Read more...
Research on Fetal Sex Differences in Predicting Spontaneous Preterm Birth Using Sera’s Proteomic Technology to be Presented at The 64th Annual Society for Reproductive Investigation Meeting
SALT LAKE CITY, March 13, 2017 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s healthcare company, today announced that research using Sera’s Read more...
